CURE’s non-Hodgkin lymphoma (NHL) page is an extensive resource of cancer information featuring the latest NHL news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on non-Hodgkin lymphoma.
May 18th 2024
One night, I had a dream that I played chess with Death and well, I won.
FDA Approves Rituxan Biosimilar to Treat Blood Cancers
July 23rd 2019The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.
Committee Supports FDA Approval of CT-P10 for Non-Hodgkin Lymphoma Treatment
October 10th 2018The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted 16-0 in support of the agency granting approval to CT-P10, a biosimilar of Rituxan (rituximab), which is a drug used to treat non-Hodgkin lymphoma.